Immune checkpoint inhibitor-associated pneumonia
Conditions
Interventions
Group A:The NCCN treatment protocol
Group B:Expert consensus on CIP treatment protocol in China
Group C:The CIP treatment protocol based on pathological, pathophysiological and imaging features
Sponsors
The First Affiliated Hospital of Nanjing Medical University(Jiangsu Province Hospital)
Eligibility
Sex/Gender
All
Age
18 Years to 85 Years
Inclusion criteria
Inclusion criteria: 1.aged over 18 years old; 2.Pathologically confirmed cancer; 3.Treated with ICIs ; 4. Emerging pulmonary shadows (such as ground glass shadows, plaque consolidation shadows, interlobular septal ;thickening, mesh shadows, tractive bronchiectasis and fibrous cord shadows, etc.); 5. Except pulmonary infection, lung tumor progression, pulmonary interstitial disease caused by other causes, pulmonary vasculitis, pulmonary embolism and pulmonary edema; 6.Subjects voluntarily join the study,sign the informed consent,have good compliance and cooperate with the follow-up.
Exclusion criteria
Exclusion criteria: CIP patients who were unable to complete the full study and voluntarily dropped out.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Chest CT manifestation;Related blood indicators;Clinical manifestation;Pulmonary function;Arterial blood gases;Cytological classification of bronchoalveolar lavage fluid;Lung biopsy pathology; | — |
Countries
China
Contacts
Public ContactMao Huang
The First Affiliated Hospital of Nanjing Medical University (Jiangsu Province Hospital)
Outcome results
None listed